Alnylam Pharmaceuticals has a total of 5287 patents globally, out of which 1981 have been granted. Of these 5287 patents, more than 52% patents are active. United States of America is where Alnylam Pharmaceuticals has filed the maximum number of patents, followed by Europe and Australia. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals was founded in the year 2002. The Company operates as an early-stage therapeutics company. The Company discovers and develops drug and medicines for the treatment of human disease. Company serves health care sectors in the United States and the United Kingdom. As of April 2023, the market cap of Alnylam Pharmaceuticals is $25.19 Billion.
Do read about some of the most popular patents of Alnylam Pharmaceuticals which have been covered by us in this article and also you can find Alnylam Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Alnylam Pharmaceuticals patent portfolio.
How many patents does the founder and the CEO of Alnylam Pharmaceuticals have?
The founders Christoph Westphal has 14 patents, David Bartel has 5 patents, John Clarke has 80 patents, Paul Schimmel has 21 patents, Phillip D. Zamore has 46 patents, Phillip Sharp has 0 patent, Robert Langer has 102 patents and Thomas Tuschl has 22 patents. The CEO John Maraganore has 14 patents.
How many patents does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has a total of 5287 patents globally. These patents belong to 894 unique patent families. Out of 5287 patents, 2754 patents are active.
How Many Patents did Alnylam Pharmaceuticals File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Alnylam Pharmaceuticals Applications Filed | Alnylam Pharmaceuticals Patents Granted |
| 2023 | – | 11 |
| 2022 | 192 | 169 |
| 2021 | 290 | 172 |
| 2020 | 259 | 146 |
| 2019 | 221 | 149 |
| 2018 | 206 | 175 |
| 2017 | 181 | 162 |
| 2016 | 242 | 123 |
| 2015 | 312 | 128 |
| 2014 | 339 | 132 |
| 2013 | 235 | 103 |
| 2012 | 271 | 129 |
| 2011 | 287 | 101 |
Which Alnylam Pharmaceuticals Drug Patents are Expiring in the Next 10 Years?
The patent no. US11401517B2 which is expiring in Aug, 2035, describing using siRNA gene therapeutics to treat conditions by suppressing gene silencing activity. The treatment involves administering RNAi duplex agents with specific motifs that effectively inhibit the expression of target genes. Additionally, there are RNAi compositions designed for therapeutic use.
Given below is the list of few drugs patented by Alnylam Pharmaceuticals accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Amvuttra | US11401517B2 | Modified Double-Stranded RNA Agents | Aug, 2035 |
| Onpattro | US8802644B2 | Lipid Formulation | Oct, 2030 |
| Givlaari | US10131907B2 | Glycoconjugates Of RNA Interference… | Aug, 2028 |
| Oxlumo | US8106022B2 | Carbohydrate Conjugates As Delivery… | Aug, 2028 |
Interested in knowing about Alnylam Pharmaceuticals Drug Patents Expiring in the next 10 years?
How many Alnylam Pharmaceuticals patents are Alive/Dead?
How Many Patents did Alnylam Pharmaceuticals File in Different Countries?
Countries in which Alnylam Pharmaceuticals Filed Patents
| Country | Patents |
| United States Of America | 1179 |
| Europe | 547 |
| Australia | 416 |
| Japan | 384 |
| Canada | 273 |
| Germany | 196 |
| China | 139 |
| Hong Kong (S.A.R.) | 138 |
| Mexico | 119 |
| India | 108 |
| United Kingdom | 101 |
| Israel | 98 |
| Brazil | 83 |
| Singapore | 68 |
| New Zealand | 65 |
| Spain | 64 |
| Taiwan | 63 |
| South Africa | 59 |
| Argentina | 53 |
| Denmark | 52 |
| Korea (South) | 45 |
| Austria | 41 |
| Eurasia | 32 |
| Chile | 26 |
| Portugal | 24 |
| Indonesia | 22 |
| Hungary | 21 |
| Poland | 21 |
| Norway | 21 |
| Slovenia | 17 |
| Viet Nam | 17 |
| Croatia | 16 |
| Malta | 16 |
| Lithuania | 15 |
| Macao | 15 |
| Malaysia | 13 |
| Italy | 13 |
| Colombia | 12 |
| Philippines | 12 |
| Cyprus | 11 |
| Peru | 11 |
| Albania | 10 |
| Russia | 9 |
| Dominican Republic | 8 |
| Africa | 7 |
| Costa Rica | 7 |
| Serbia | 7 |
| Uruguay | 6 |
| Panama | 6 |
| Jordan | 5 |
| Africa | 5 |
| Guatemala | 4 |
| Paraguay | 4 |
| Morocco | 3 |
| Tunisia | 3 |
| Bolivia | 3 |
| Netherlands | 3 |
| Luxembourg | 3 |
| Kenya | 2 |
| Pakistan | 2 |
| Gulf Cooperation Council | 2 |
| France | 2 |
| Montenegro | 2 |
| Nicaragua | 1 |
| Saudi Arabia | 1 |
| Turkey | 1 |
| San Marino | 1 |
| Thailand | 1 |
| Ecuador | 1 |
Where are Research Centres of Alnylam Pharmaceuticals Patents Located?
10 Best Alnylam Pharmaceuticals Patents
US8106022B2 is the most popular patent in the Alnylam Pharmaceuticals portfolio. It has received 665 citations so far from companies like Regulus Therapeutics, Isis Pharmaceuticals and Ionis Pharmaceuticals.
Below is the list of 10 most cited patents of Alnylam Pharmaceuticals:
| Publication Number | Citation Count |
| US8106022B2 | 665 |
| WO2008042973A2 | 658 |
| WO2010054406A1 | 621 |
| WO2010129709A1 | 584 |
| WO2010144740A1 | 536 |
| WO2009086558A1 | 532 |
| US20030206887A1 | 498 |
| US6617438B1 | 429 |
| WO2010054401A1 | 426 |
| US20030190635A1 | 410 |
How many inventions of other companies were rejected due to Alnylam Pharmaceuticals patents?
The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Alnylam Pharmaceuticals invention. They couldn’t because Alnylam Pharmaceuticals had protected those before them.
Examiners at the USPTO referred 348 Alnylam Pharmaceuticals patents in 1701 rejections (35 USC § 102 or 35 USC § 103 types).
The top citing companies in the Alnylam Pharmaceuticals patent portfolio are National Institutes of Health, Ionis Pharmaceuticals and Sirna Therapeutics.
List of the Companies whose Patents were rejected citing Alnylam Pharmaceuticals –
| Company | Number of Patent Applications that faced Rejection Citing Alnylam Pharmaceuticals Patents | Number of Rejections (102 & 103) |
| National Institutes Of Health | 37 | 76 |
| Ionis Pharmaceuticals | 37 | 77 |
| Sirna Therapeutics | 23 | 52 |
| Dicerna Pharmaceuticals | 22 | 59 |
| Arbutus Biopharma | 20 | 66 |
| Merck Sharp & Dohme | 16 | 26 |
| Arrowhead Pharmaceuticals | 16 | 30 |
| City Of Hope | 12 | 18 |
| Arrowhead Research | 11 | 21 |
| Roche Innovation Center | 9 | 21 |
Count of 102 and 103 Type Rejections based on Alnylam Pharmaceuticals Patents
Top Alnylam Pharmaceuticals Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US8202979B2 | 25 |
| US20030206887A1 | 18 |
| US20060211642A1 | 16 |
| US7582744B2 | 15 |
| US8598333B2 | 14 |
| US8106022B2 | 14 |
| US7745608B2 | 11 |
| US20050096284A1 | 11 |
| US20050153337A1 | 10 |
| US8168775B2 | 10 |
| US7176304B2 | 9 |
| US8097710B2 | 9 |
| US8110674B2 | 9 |
| US20050176025A1 | 8 |
| US20050137153A1 | 8 |
What Percentage of Alnylam Pharmaceuticals US Patent Applications were Granted?
Alnylam Pharmaceuticals (Excluding its subsidiaries) has filed 765 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 373 have been granted leading to a grant rate of 63.44%.
Below are the key stats of Alnylam Pharmaceuticals patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Alnylam Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Mccarter & English | 196 | 66.67% |
| Alnylam Fenwick | 141 | 45.54% |
| Cozen O Connor | 62 | 67.74% |
| Goodwin Procter | 61 | 100.00% |
| Viksnins Harris Padys Malen | 51 | 59.57% |
| Fish & Richardson | 36 | 50.00% |
| Alnylam Pharmaceuticals | 32 | 75.00% |
| David S Resnick | 32 | 43.33% |
| Lando & Anastasi | 18 | 50.00% |
| Fish & Richardson | 16 | 81.25% |